Category Archives: Pr Newswire

2024 China Tianjin Binhai New Area Talent Innovation and Entrepreneurship Competition (Overseas Competition) Singapore Division Finals to Begin Soon

Smart Binhai, Glorious Competition! SINGAPORE, Aug. 10, 2024 /PRNewswire/ — With the success of the Hong Kong SAR Final Round of the 2024 China Tianjin Binhai New Area Talent Innovation and Entrepreneurship Competition (Overseas Competition) on 17th July, the Finals of the Singapore Division is about to kick off on 15th August. As the gateway to […]

11,000 Global Financial Insurance Elites Converge in Kuala Lumpur. International Dragon Award IDA members share glorious moments

A grand celebration of insurance knowledge and honor, united in wisdom and glory. KUALA LUMPUR, Malaysia, Aug. 10, 2024 /PRNewswire/ — The 15th Worldwide Chinese Life Insurance Congress & 2024 IDA Annual Conference is being held at the Malaysia International Trade and Exhibition Centre (MITEC) from August 9 to 12, 2024. This year’s theme, “CHANGE […]

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request […]

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100. Supportive data from preclinical study in atherosclerosis, a common obesity-related metabolic complication, is expected to be available H2-2024. […]

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today […]

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to four new employees. Fulcrum granted stock options to purchase shares of the […]

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Phase 1b & 2/3 (“DRAGON II”) trial of Tinlarebant in adolescent STGD1 patients has been initiated and have completed enrollment for Phase 1b with six […]

SEG Solar Inaugurates Houston Module Plant and Rolls Out First Module

HOUSTON, Aug. 10, 2024 /PRNewswire/ — On August 8, 2024, SEG Solar (SEG), a leading U.S. photovoltaic manufacturer, held a grand opening ceremony for its new PV manufacturing base in Houston, Texas, marking a new chapter in SEG’s commitment to U.S. domestic manufacturing. During the ceremony, the first 585W YUKON N series module rolled off the […]

GenScript Biotech Reports First Half 2024 Results

Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development  Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy revenue and a 75.4% rise in gross profit, showcasing strong performance across key segments. Focused on Innovation and Efficiency: Investing […]

Global IBO Group Ltd., an Integrated AIGC Animation Platform Provider, Announce Definitive Business Combination Agreement With Bukit Jalil Global Acquisition 1 Ltd.

NEW YORK, Aug. 9, 2024 /PRNewswire/ — Global IBO Group Ltd. (“GIBO”), a unique and integrated AIGC animation creation and streaming platform for storytellers and content creators, and Bukit Jalil Global Acquisition 1 Ltd. (“Bukit Jalil Global”) (Nasdaq: BUJA), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive […]